Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation,
inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been …

Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for
COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …

As of April 4, 2020, coronavirus disease-2019 (COVID-19) has been confirmed in 1,395,136
people worldwide, with a mortality of approximately 5.8%. Since the COVID-19 outbreak …

Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine
storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of …

Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …

The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …

In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6
(IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed …

Coronaviruses may activate dysregulated host immune responses. As exploratory studies
have suggested that interleukin‐6 (IL‐6) levels are elevated in cases of complicated Covid …